L'Institut Pasteur de Tunis et sa stratégie en biosécurité/biosûerté

Institut Pasteur de Tunis

More than 120 years dedicated to Public Health

www.pasteur.tn


Charles Nicolle, directeur de l’ Institut Pasteur de Tunis de1903 à 1936. Prix Nobel de Médecine, 1928

Institut Pasteur de Tunis en 1905Depuis le départ, des découvertes majeurs ont été réalisées (la transmission du typhus, l’agent de la toxoplasmose, la leishmaniose viscérale, le concept de maladie inapparente)

Création en 1893

19/10/2016 3Institut Pasteur de Tunis

Councils: • Administrative Council (16 members)• Scientific Council : DG + 8 elected members from IPT• Enlarged Scientific Council: SC+4 Tunisians from outside IPT+4 internationals


Missions: • Biomedical Analysis and Public Health Activities• Production of therapeutic sera and vaccines• Research & development• Training

• Medical Ethics Committee • Communication, valorization and technology transfer• Committee on Health and Safety• Training committee• Bioressources • Quality

Committees


Biomedical Ethics Committee of the IPT

Since 1992 this Committee is registered at the Office of Human Research Protections (OHRP) in the United States (number IRB00005445 registration FWA00010074) and committed to follow the Declaration of Helsinki for institutional medical research involving human subjects, including research on human material and personal data.

Process: review after request the protocols, objectives and methodologies to deliver authorization

Missions:- identify and ensure the minimization of associated with the

research, - identify the benefits that would bring this research, - ensure that potential subjects will be informed of a precise and fair

manner, risks or discomforts and profit for this research.


Board of Health and Safety at Work

Ensures compliance with the rules of hygiene and security staff Missions: • prepare draft regulations and requirements for health and

safety at work within the Institute, • Information, awareness-raising in the field of health and safety

in the workplace. • Provide programs for the prevention of occupational risks

within the Institute and to monitor the implementation of the programs adopted.

• Manage an accident or an occupational disease serious


Biological Resources Committee

Created in August 2014,

- the request for the creation of a centre for clinical research (CIC)

Missions: - State of play

- of the collections (microbiological, DNA, sera, tissues, cells, other) and information related to allow the identification of the means available

- under the conditions of storage of samples and data related to the improvement of the conservation conditions

- specification to preserve these collections (conservation conditions (software for management, etc.) in respect of ethics, procedures in force and standards (protection of personal data, consent, etc.).


IPT Quality Program

• The Quality Assurance service was established in December 1998 for the implementation of a quality system covering the activities of development, production and control of vaccines and serums.

• In accordance with the memorandum of January, 2015, it established a Quality Management System Steering Committee (QMSC) at the Pasteur Institute in Tunis. It is called the "Committee Quality of the Pasteur Institute in Tunis."

Objectives:

- Maintaining the quality and development of the QMS approach;- Design and management of short and medium-term quality policy; and- Continuation of the accreditation process of involved laboratories.


Workers

Sci-en-tistsTech-

nicians

Admin-istratio-nengi-neers

Global: 502 Scientists: 119

Human ressoursesInstitut Pasteur de Tunis (2015)

Public Health

Biomedical Analysis and Public Health activities

• 18 laboratories + 2 services (35 biologists): Cover the quasi-totality of clinical biology tests. IPT is recognized for the expertise of some of the laboratories in the specialized medical biology.

• IPT hosts several national (rabies, poliomyelitis, measles, bacteria, other) or international reference centers (for the Eastern Mediterranean Region/WHO: for poliomyelitis and measles, HPV)

• IPT is a center for vaccination (for the travelers) and a center for rabies treatment and vaccination (free).

Bioproduction activities• BCG vaccine

- BCG + solvant- Immun BCG

• Therapeutic sera:- Anti-scorpions : Androctonus australis, Buthus occitanus - Anti-vipera: Cerastes cerastes, Vipera lebetina - Anti-rabies

Sérums antiscor-pionique

Sérums antivipérins Sérums antirabique Vaccin BCG Immun BCG TOTAL

41581299

13170

23800

6265

48692

80703284

12550

46790

7314

78008

4372 22968240

41568

8759

65235

71422627

6980

56741

9155

82645

2011 2012 2013 2014

Research and training

Training activities

• IPT linked to University Tunis El Manar

• Activities with the various universities and at international level

• Organization of theoretical and practical courses in the various domains of the biology, new technologies

• Direction of PhDs of various national and international universities (sciences, medicine, others)


Thèse

s

Mastères

PFE/in

génieurat

Thèse

s de m

éédecine

Thése

s de m

édecine vétérin

aire

Thèse

s de pharm

acieTO

TAL

19

75

37

2 7 3

143

28

68

43

5 7 4

155

13

70

32

120 1

128

10

4033

3 4 3

93

2012 2013 2014 2015

Diplômes soutenus (2012-2015)


Thèse

s

Mastères

PFE/in

génieurat

Thèse

s de m

édecine

Thése

s de m

édecine vétérin

aire

Thèse

s de pharm

acie Total

154

57

12 7 0 3

233

138

372 4 4 0

185180

263 3 0 5

217

158

5327

4 3 4

249

2012 2013 2014 2015

Diplômes en cours/Nombre d’étudiants


7 6

27

10

50

10 7

25

5

47

8 7

25

11

51

8 9

27

13

57

2012 2013 2014 2015

Evénements (Formation, workshop, cours, etc.)


Eastern Mediterranean Regional Training Centre selectedTDR news item 5 May 2015

The Institut Pasteur de Tunis in Tunis, Tunisia, has been selected to be the Eastern Mediterranean Regional Training Centre supported by TDR. This is the sixth and final centre to be chosen for the TDR network, which is designed to expand and coordinate training courses across multiple countries, leading to improved use of health interventions.

Ethics: Adapting and using the World Health Organization’s training on ethics for the Tunisian environment and improving the skills of the Tunis Institutional Review Board.Good health research practice: Training trainers and researchers with the TDR good clinical practice and good clinical laboratory practice courses, as well as the Good Health Research Practice course.Implementation research: Beginning implementation research courses using the TDR implementation research toolkit, and working with TDR and others to develop a massive open online course (MOOC) on implementation research focused on infectious diseases of poverty.


Research & development

Field of activities Infectious diseases +++ (national health priorities)

Leishmaniasis, hydatidosis, tuberculosis, viral hepatitis, rabies, papillomavirus, enteroviruses, avian virus, other veterinary microbial diseases, etc.

Scorpion and snake biochemistry/immunology Congenital immune deficiencies/immune disorders Genetic susceptibility to metabolic and infectious

diseases, cancer R&D biotechnology and bioprocesses (rabies, measles,

Hepatitis C, veterinary vaccines) Bioinformatics and Mathematical modeling Entomology Clinical Epidemiology and Control (including clinical trials)



Research & development

Financial support

• National support through the eligibility of the groups to be Research Laboratories (9) supported by the Tunisian Ministry of Higher Education and Scientific Research

• International financial supports from European Commission-PCRD; World Health Organization/TDR; National Institutes of Health; Walter Reed Army Institute of Research; International Agency of Atomic Energy; The Wellcome Trust; Agence Nationale de Recherche; OTAN; The network of Pasteur Institutes-RIIP; NEPAD; TWAS; notably).

• PCI Internal Collaborative Program, 2nd year.


ANR (Paris, France) R&DBIO-RAD (Paris, France) Patent strengtheningEuropean Commission (Brussels, Belgium) R&DFondation Mérieux (Lyon, France) Euro-Mediterranean Public Health

Information SystemFort Dodge Animal Health Vaccine development and validationInternational Atomic Energy Agency (Vienna, Austria) R&D capacity building and trainingInstitut Pasteur International Network(Paris, France) R&D and Public Health Activities (control)Joint WHO/EMRO-COMSTECH(Islamabad, Pakistan) R&DNational Institutes of Health (Maryland, USA) R&D, clinical researchNorth Atlantic Treaty Organization (Brussel, Belgium) R&DThe New Partnership for Africa’s Development (Johannesburg, South Africa) R&DWalter Reed Army Institute Of Research (USA) Clinical trials (phase II and phase III)Welcome Trust (London, UK) R&D, trainingWHO/EMRO (Cairo, Egypt) R&D for controlWorld Health Organization TDR (Geneva, Switzerland) R&D, capacity building, training

Funding agencies (alphabetic order) Nature of the grant

Research and trainingCSE-Juin 2011

International Partners of Institut Pasteur de Tunis

17 funding agencies~ 50 ongoing research projects

More than 75 partners institutions in 28 countries


Publications, Citations, (Source Wos, Mars 2016)


201: Partners Institutions: 64 countries

Austria

Nigeria

Qatar

Singapore

South Korea

Brazil

Lebanon

Oman

Uruguay

Kuwait

Russia

Saudi Arabia

Canada

India

Greece

Iran

Belgium

Germany

England

USA

222222222233333334444455666

9101011111213

1616

2124

35113

International Partners in IPT publications (Wos; 5 years: 2011-2014: 418 publications)


Chimeric polypeptide useful as a medicament comprises a selectin C-type lectin domain joined through a linker to an integrin von Willebrand A domain having a metal ion-dependent adhesion site (FR2909672, 2008-06-13) FATHALLAH MOHAMED DAHMANI; JARBOUI MOHAMED ALI; DELLAGI MOHAMED KOUSSAY

METHOD FOR PREPARING RECOMBINANT MYCOBACTERIAL POLYPEPTIDES IN YEAST AND THEIR USE IN DIAGNOSIS OF MYCOBACTERIAL RELATED DISEASES (WO2008010096, 2008-01-24 ). FATHALLAH MOHAMED DAHMANI (TN); BARBOUCHE MOHAMED RIDHA (TN); HO JOHN L (US); BENABDESSELEM CHAOUKI (TN); DELLAGI KOUSSAY (TN); LARGUECHE BEYA (TN)

RECOMBINANT PICHIA PASTORIS STRAINS AND PROCESS FOR THE PRODUCTION OF RECOMBINANT HUMAN INTERFERON ALPHA (WO2007099462, 2007-09-07) FATHALLAH MOHAMED DAHMANI (TN); KALLEL HELA (TN); DELLAGI KOUSSAY (TN); REBHI IMEN (TN); AYED ATEF (TN)

MAUROCALCINE, ANALOGUES THEREOF AND THEIR THERAPEUTICAL USES (DE60126067D, 2007-03-08) KHARRAT RIAD (TN); MABROUK KAMEL (FR); EL-AYEB MOHAMMED (TN); ROCHAT HERVE (FR); SABATIER JEAN-MARC (FR)

GENE ASSOCIATED WITH LEISHMANIA PARASITE VIRULENCE (YU99603, 2006-05-25) BEN ACHOUR YOSSER (TN); CHENIK MEHDI (TN); LOUZIR HECHMI (TN); DELLAGI KOUSSAY (TN)

POLYPEPTIDES OF LEISHMANIA MAJOR AND POLYNUCLEOTIDES ENCODING SAME AND VACCINAL, THERAPEUTICAL AND DIAGNOSTIC APPLICATIONS THEREOF (WO2006108720, 2006-10-19) CHENIK MEHDI (TN); LAKHAL SAMI (TN); LOUZIR HECHMI (TN); DELLAGI KOUSSAY (TN)

COMPOSITION COMPRISING THE N-TERMINAL REGION OF LEISHMANIA HISTONE H2B, USE THEREOF FOR INDUCING AN IMMUNE RESPONSE (WO2006097642, 2006-09-21) CHENIK MEHDI (TN); LOUZIR HECHMI (TN); DELLAGI KOUSSAY (TN)

LEISHMANIA ANTIGENS SUITABLE FOR A DIAGNOSTIC KIT OF LEISHMANIA (WO2006079565, 2006-08-03) DELLAGI KOUSSAY (TN); KAMOUN-ESSGHAIER SAYDA (TN); GUIZANI IKRAM (TN)

USE OF ZKW PEPTIDE FOR PREPARING AN INHIBITOR DRUG AGAINST PLATELET AGGREGATION (WO2005014021, 2005-02-17) MARRAKCHI NAZIHA (TN); MABROUK KAMEL (FR); SABATIER JEAN-MARC (FR); EL AYEB MOHAMED (TN); ROCHAT HERVE (FR)

Amino-butyrate derivatives of venoms (GB2335923, 1999-10-06) SABATIER JEAN-MARC (FR); EL-AYEB MODHAMMED (TN); VAN RIETSCHOTEN JURPHAAS (FR); ROCHAT HERVE (FR)

LEBETIN PEPTIDES AS PLATELET AGGREGATION INHIBITORS (WO9829436, 1998-07-09) ROCHAT HERVE (FR); MABROUK KAMEL (FR); EL-AYEB MOHAMMED (TN)

VACCINE COMPOSITION COMPRISING RECOMBINANT BCG EXPRESSING GP63 FUSION PROTEIN (WO9610081, 1996-04-04) GICQUEL BRIGITTE (FR); ABDELHAK SONIA (FR); DELLAGI KOUSSAY (TN); LOUZIR HECHMI (TN)

Patents


The Institut PasteurInternational Network


ANDI Centre of Excellence for Bio-molecules Discovery


African Network for Drugs and Diagnostics Innovation (ANDI), United Nations Economic Commission for Africa (UNECA), Menelik II Avenue, PO Box 3001, Addis Ababa, Ethiopia. Tel: +251 11 544 362; E-mail: [email protected]

Promote African-led health product innovation to address African’s public health needs through efficient use of local knowledge, research networks and building of capacity


The American Association for Advancement in Science with Institut Pasteur in Tunis, the Faculty of Sciences in Tunis & The University of Cairo , organized a workshop : International Engagement: Responsible BioScience for a Safe and Secure Society. December, 31th octobre – November, 1st 2011.

Aims to bring together researchers and scientists from American and MENA Regions in biological sciences around themes such as bioethics, biosafety related to Public Health.

legal, ethical and security issues related to research in the field of infectious diseases, as well as the establishment of international networks between scientists from the Middle East, North Africa, Afghanistan, Pakistan and the American and European continents.

IPT commitment in B&B


May, 24 - 25 2012, the Faculty of Science of Tunis (Tunis El Manar University), in collaboration with Georgetown University, organized a seminar on "Ensuring safe driving, safe and ethical biomedical and behavioral research in Tunisia “ at the Institut Pasteur inTunis.

• Awareness Tunisian researchers, clinicians, research administrators, policy makers, and students of bioethics and biosafety

• Help ensure that participants will examine these aspects in their work using the best practices in the field of bioethics and biosafety


IPT and biological risk management

WHO: The training of trainers in biological risk management and biosecurity of laboratories: 2 Experts trainers

UNICRI, EU Centre of Excellence CBRN: project 3: the development of knowledge and the transfer of best practices for the biological risk management, biosafety and biosecurity: 2 national experts and an e-learning plate-form hosted at IPT

Tunisian-German co-operation and partnership MAE / IPT / DSSB / ONMNE / GIZ / RKI): Excellence in the management of biological and health risks


IPT and RKI collaboration: Biosecurity, Biosafety, Detection and Diagnosis

• Acquisition of skills and equipment: Clinical Virology and Rabies laboratories

• Joint training in B & B and BM in Tunis and Berlin

• responsible research / dual use of concern / code of conduct

Improving : the diagnostic ability of highly

pathogenic virus the ability to prevent biological risks

Health & Medicine

L'Institut Pasteur de Tunis et sa stratégie en biosécurité/biosûerté